Compare PT Telekomunikasi Indonesia Tbk (TLK) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
PT Telekomunikasi Indonesia Tbk vs Travere Therapeutics Inc. Common Stock — how do they compare? PT Telekomunikasi Indonesia Tbk trades at $12.71 (market cap $12.31B), while Travere Therapeutics Inc. Common Stock trades at $52.74 (market cap $4.88B). The key difference: PT Telekomunikasi Indonesia Tbk is far larger — about 2.5× Travere Therapeutics Inc. Common Stock's market cap, and PT Telekomunikasi Indonesia Tbk pays a 9.66% dividend while Travere Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold PT Telekomunikasi Indonesia Tbk for 1 Days and Travere Therapeutics Inc. Common Stock for 0 Days on average.
| TLK | TVTX | |
|---|---|---|
Market Cap | $12.31B | $4.88B |
Volume | 964,895 | 1,668,577 |
Sector | Media | Health |
52-Week High | $23.43 | $67.52 |
52-Week Low | $12.42 | $26.79 |
Typical Hold Time | 1 Days | 0 Days |
Enterprise Value | $13.67B | $5.01B |
Dividend Yield | 9.66% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TLK trades at $12.65, down 1.02% on the day, with a bearish technical signal driven by moving averages. The stock shows mixed earnings performance with two recent misses but a Q2 2026 beat. Fundamentals remain solid with a 66.88% gross margin and attractive valuation at P/E of 12.72 and EV/EBITDA of 3.27. Recent news includes a 52-week low hit in September 2026 and institutional buying activity.
The outlook is cautious with 100% hold ratings from analysts and bearish technical indicators. Investment opportunity lies in deep value metrics and positive 5G developments, but risks include earnings volatility and competitive pressures in the telecommunications sector.
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About PT Telekomunikasi Indonesia Tbk
Telkom Indonesia provides mobile, fixed-line, broadband, and digital services in Indonesia. Its businesses include Telkomsel, which serves the country’s mobile market.
Read more on TLK →About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →
